BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30536180)

  • 1. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
    Minakata D; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
    Int J Hematol; 2019 Feb; 109(2):141-146. PubMed ID: 30536180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.
    Minakata D; Fujiwara SI; Hayakawa J; Nakasone H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
    Acta Haematol; 2020; 143(3):250-259. PubMed ID: 31461700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis.
    Taenaka N; Shimada Y; Hirata T; Nishijima MK; Takezawa J; Yoshiya I; Kambayashi J
    Crit Care Med; 1983 Sep; 11(9):735-8. PubMed ID: 6411432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of disseminated intravascular coagulation (DIC) or pre-DIC with gabexate mesilate (FOY)].
    Wada H; Suzuki H; Mori Y; Deguchi A; Oukubo I; Tsuda M; Tanaka I; Deguchi K; Shirakawa S; Minami N
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):67-73. PubMed ID: 3132518
    [No Abstract]   [Full Text] [Related]  

  • 5. [Synthetic protease inhibitors in the treatment of disseminated intravascular coagulation].
    Aramoto H; Saito H; Shigematsu H; Muto T
    Nihon Rinsho; 1993 Jan; 51(1):93-8. PubMed ID: 8433532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.
    Chen CL; Wang SD; Zeng ZY; Lin KJ; Kao ST; Tani T; Yu CK; Wang JY
    J Allergy Clin Immunol; 2006 Jul; 118(1):105-12. PubMed ID: 16815145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.
    Nishiyama T; Kohno Y; Koishi K
    Am J Emerg Med; 2012 Sep; 30(7):1219-23. PubMed ID: 22204993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of disseminated intravascular coagulation with gabexate mesilate.
    Tamaki S; Wada H; Hiyoyama K; Shimura M; Minamikawa K; Wakita Y; Nakase T; Ohiwa M; Kaneko T; Iwasaki E
    Clin Ther; 1993; 15(6):1076-84. PubMed ID: 8111805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gabexate as a therapy for disseminated intravascular coagulation.
    Umeki S; Adachi M; Watanabe M; Yaji S; Soejima R
    Arch Intern Med; 1988 Jun; 148(6):1409-12. PubMed ID: 3132124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of pre-disseminated intravascular coagulation state with gabexate mesilate (FOY)].
    Wada H; Suzuki H; Deguchi A; Mori Y; Okubo I; Tsuda M; Nagano T; Deguchi K; Shirakawa S
    Rinsho Ketsueki; 1986 Dec; 27(12):2243-8. PubMed ID: 3106677
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
    Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
    Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the effects of primary therapy for DIC following circulatory arrest.
    Takemoto Y; Tanaka S; Tanabe J; Nakamura Y; Kohama A; Shibata S
    Am J Hematol; 1986 Apr; 21(4):377-82. PubMed ID: 3082185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of FOY on DIC patients associated with hematological neoplastic disorders. Hanshin Cooperative Study Group of Hematological Disorders].
    Taniguchi N; Kitani T; Kawagoe H; Horiuchi A; Masaoka T; Yasunaga K; Okamoto Y; Ohkubo A; Yonezawa T; Nagai K
    Rinsho Ketsueki; 1987 Oct; 28(10):1729-37. PubMed ID: 3133506
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.
    Dabrowski A; Gabryelewicz A
    J Physiol Pharmacol; 1994 Sep; 45(3):455-65. PubMed ID: 7841457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disseminated intravascular coagulation (DIC) after artificial valve replacement: especially tricuspid regurgitation].
    Satokawa H; Iwaya F; Igari T; Abe T; Hagiwara K; Tanji M; Watanabe M; Midorikawa H; Sato Y; Takase S
    Kyobu Geka; 1990 Apr; 43(4):271-5. PubMed ID: 2112659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of FOY therapy for DIC or pre-DIC associated with neurosurgical disease].
    Wakui K; Takemae T; Kobayashi S
    No Shinkei Geka; 1990 Jul; 18(7):609-17. PubMed ID: 2118601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia.
    Ookura M; Hosono N; Tasaki T; Oiwa K; Fujita K; Ito K; Lee S; Matsuda Y; Morita M; Tai K; Negoro E; Kishi S; Iwasaki H; Ueda T; Yamauchi T
    Medicine (Baltimore); 2018 Nov; 97(44):e12981. PubMed ID: 30383650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Disseminated intravascular coagulation (DIC) following open heart surgery and great vessel surgery. The result of early administration of gabexate mesilate (FOY)].
    Chihara K; Akiyama F; Shinozaki T; Shimamoto M; Takahashi K; Imura H; Yamazaki F; Kawarazaki S
    Kyobu Geka; 1984 Aug; 37(8):606-13. PubMed ID: 6438381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.